A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

McQuade, Jennifer L.; Homsi, Jade; Torres‐Cabala, Carlos A.; Bassett, Roland L.; Popuri, Rashmi Murthy; James, Marihella; Vence, Luis M.; Hwu, Wen Jen

doi:10.1186/s12885-018-5193-9

Cited by 36 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the above, several clinical trials using liposomes as carrier system for vaccine have reported safety, capability of inducing prolonged antigen-specific CD4 + and CD8 + T cell responses, as well as prolonged survival in various cancers, including non-small-cell lung carcinoma (NSCLC) ( 166 ), melanoma ( 167 , 168 ), follicular lymphoma ( 169 ) ovarian ( 170 ), breast and prostate cancers ( 171 ).…”

Section: Delivery System As Adjuvantsmentioning

confidence: 99%

Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments

et al. 2021

View full text Add to dashboard Cite

Although the discovery and characterization of multiple tumor antigens have sparked the development of many antigen/derived cancer vaccines, many are poorly immunogenic and thus, lack clinical efficacy. Adjuvants are therefore incorporated into vaccine formulations to trigger strong and long-lasting immune responses. Adjuvants have generally been classified into two categories: those that ‘depot’ antigens (e.g. mineral salts such as aluminum hydroxide, emulsions, liposomes) and those that act as immunostimulants (Toll Like Receptor agonists, saponins, cytokines). In addition, several novel technologies using vector-based delivery of antigens have been used. Unfortunately, the immune system declines with age, a phenomenon known as immunosenescence, and this is characterized by functional changes in both innate and adaptive cellular immunity systems as well as in lymph node architecture. While many of the immune functions decline over time, others paradoxically increase. Indeed, aging is known to be associated with a low level of chronic inflammation—inflamm-aging. Given that the median age of cancer diagnosis is 66 years and that immunotherapeutic interventions such as cancer vaccines are currently given in combination with or after other forms of treatments which themselves have immune-modulating potential such as surgery, chemotherapy and radiotherapy, the choice of adjuvants requires careful consideration in order to achieve the maximum immune response in a compromised environment. In addition, more clinical trials need to be performed to carefully assess how less conventional form of immune adjuvants, such as exercise, diet and psychological care which have all be shown to influence immune responses can be incorporated to improve the efficacy of cancer vaccines. In this review, adjuvants will be discussed with respect to the above-mentioned important elements.

show abstract

Section: Delivery System As Adjuvantsmentioning

confidence: 99%

Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some of the nanoparticle vaccines have been evaluated in clinical trials for different cancers (reviewed in [84][85][86]). Among all, liposomes have been used extensively due to their versatility, including Tecemotide™ liposomes [87][88][89], AS15™ lipids [90][91][92], DepoVax™ liposomes [93][94][95], Iscomatrix [96], Cholesteryl pullulan (CHP) nanogels [97], and virus-like nanoparticles [98,99].…”

Section: Nanoparticles In Clinical Trialsmentioning

confidence: 99%

Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines

Tornesello

Tagliamonte

Tornesello

et al. 2020

Cancers

View full text Add to dashboard Cite

Nanoparticles represent a potent antigen presentation and delivery system to elicit an optimal immune response by effector cells targeting tumor-associated antigens expressed by cancer cells. Many types of nanoparticles have been developed, such as polymeric complexes, liposomes, micelles and protein-based structures such as virus like particles. All of them show promising results for immunotherapy approaches. In particular, the immunogenicity of peptide-based cancer vaccines can be significantly potentiated by nanoparticles. Indeed, nanoparticles are able to enhance the targeting of antigen-presenting cells (APCs) and trigger cytokine production for optimal T cell response. The present review summarizes the categories of nanoparticles and peptide cancer vaccines which are currently under pre-clinical evaluation.

show abstract

“…Similarly, Anti-CTLA-4 has low level of ORR ( 14 , 15 ). Moreover, the ORR of HDIL-2 monotherapy is 10%–19% with complete ORR of 6%–8% ( 16 ). Therefore, how to improve the ORR of immunotherapy and how to select appropriate indicators to predict the effectiveness of immunotherapy are the two hotspots of current research.…”

Section: Limitations Of Conventional Tumor Immunotherapiesmentioning

confidence: 99%

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy

Peng

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment.

show abstract

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Cited by 36 publications

References 26 publications

Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments

Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments

Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy

Contact Info

Product

Resources

About